The emerging role of NO and IGF-1 in early renal hypertrophy in STZ-induced diabetic rats

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 3, 2011, Pages 235-243

  Levin Iaina, Nomy ^a   Iaina, Adrian ^b   Raz, Itamar ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b AFK Health ^*  (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Diabetic nephropathy; IGF 1; Nitric oxide; Renal hypertrophy; STZ

Indexed keywords

INSULIN; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; SOMATOMEDIN C; STREPTOZOCIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; KIDNEY HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; ULTRAFILTRATION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FEMALE; HYPERTROPHY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; KIDNEY; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROGEN OXIDES; RATS;

EID: 79952156788     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1172     Document Type: Article

References (28)

1. Seyer-Hansen K, Hansen J, Gundersen HJG. Renal hypertrophy in experimental diabetes: a morphometric study. Diabetologia 1980; 18: 501-505.
2. Hostetter TH, Troy JI, Brenner BM. Glomerular hemodynamics in experimental DM. Kidney Int 1981; 19: 410-415.
3. Ross J, Goldman JK. Effect of STZ-induced diabetes on kidney weight and compensatory hypertrophy in the rat. Endocrinology 1971; 88: 1079-1082.
4. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental kidney disease. Diabetologia 2000; 43: 1205-1223.
5. Flyvbjerg A, Frystyk J, Osterby R, Orskov H. Kidney IGF1 and renal hypertrophy in GF-deficient diabetic dwarf rats. Am J Physiol 1992; 262: E956-E962.
6. Taylor A, Dunger DB, Preec MA, et al. The GH-independent IGFBP1, BP28, is associated with serum IGF1 inhibitory bioactivity in adolescent IDDM. Clin Endocrinol 1990; 32: 229-233.
7. Landau D, Chin E, Bondy C, et al. Expression of IGFBPs in the rat kidney: effects of long term diabetes. Endocrinology 1995; 136(5): 1835-1842.
8. Hirschberg R, Kople LD. Evidence that IGF1 increases renal blood flow and GFR in fasted rats. J Clin Invest 1989; 83: 326-330.
9. Guter HP, Eckardt KU, Zap FG, et al. IGF1 increases GFR and renal blood flow in men. ACTA Endocrinologica 1989; 121: 101-106.
10. Craven PA, DeRubertis FR, Melhem M. Nitric oxide in diabetes mellitus. Kidney Int 1997; 52(Suppl. 60): 546-553.
11. Keynan S, Hirschberg B, Levin-Iaina N, et al. Renal NO production during the early phases of experimental DM. Kidney Int 2000; 58: 740-747.
12. Flyvbjerg A, Kessler U, Dorka B, et al. Transient increase in renal IGFBPs during initial kidney hypertrophy in experimental diabetes in rats. Diabetologia 1992; 35: 589-593.
13. Raz I, Rubinger D, Popovtzer M, et al. Octreotide prevents the early increase in renal IGFBP1 in STZ diabetic rats. Diabetes 1998; 47: 924-930.
14. Bartholomew B. A rapid method for the assay of nitrate in urine using the nitrate reductase enzyme of E. coli. Food Chem Toxicol 1984; 22: 541-554.
15. 15N]nitrate in biological fluids. Anal Biochem 1982; 126: 131-138.
16. Osterby R, Brekke IB, Gundersen HJ, et al. Quantitative studies of glomerular ultrastructure in human and experimental diabetes. Appl Pathol 1984; 2: 205-211.
17. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
18. Flyvbjerg A, Hill C, Logan A. Pathophysiological role of growth factors in diabetic kidney disease: focus on innovative therapy. TEM 1999; 10: 267-272.
19. Poirier O, Nocaud V, Vionnet N, et al. Polymorphism screening of four genes encoding advanced glycation end-products putative receptors. Association study with nephropathy in type 1 diabetic patients. Diabetes 2001; 50: 1214-1218.
20. Border WA, Noble NA. Evidence that TGF-beta should be a therapeutic target in DN (letter). Kidney Int 1998; 54: 1390-1391.
21. Makino H, Sugimoto H, Shikata K. Diabetic nephropathy-recent advances in its mechanism and treatment. Nippon Rinsho 1999; 57: 590-600.
22. Wang Y, Nagase S, Koyama A. Stimulatory effect of IGF1 and VEGF on eNOS message, protein expression, eNOS phosphorylation and NO production in rat glomeruli, and the involvement of PI3-K signaling pathway. Nitric Oxide 2004; 10(1): 25-35.
23. Marthis KM, Banks RD. Role of NO and ATII in diabetic induced glomerular hyperfiltration. J Am Soc Nephrol 1996; 7: 105-112.
24. Flyvbjerg A. The role of IGF1 in initial renal hypertrophy in experimental diabetes. In GH and IGF1, Flyvbjerg A, Orskov H, Albert KGNM (eds). John Wiley and Sons: Chichester, New York, 1993.
25. Khamaisi M, Keynan S, Bursztyn M, et al. Role of renal nitric oxide synthase in diabetic kidney disease during the chronic phase of diabetes. Nephron Physiol 2006; 102(3-4): 72-80.
26. Muniyappa R, Walsh MF, Ranji JS, et al. IGF1 increases vascular smooth muscle NO production. Life Sci 1997; 61: 625-931.
27. Jaffa AA, LeRoith D, Roberts CT Jr, Rust PF, Mayfield RK. IGF1 produces renal hyperfiltration by a kinin-mediated mechanism. Am J Physiol 1994; 266: F102-F107.
28. Ren J, Duan J, Thomas DP, et al. IGF1 alleviates diabetes-induced RhoA activation, eNOS uncoupling and myocardial dysfunction. Am J Physiol Regul Interg Comp hysiol 2008; 294(3): R793-R802.